Cardiff Oncology
CRDF
66 hedge funds and large institutions have $42.3M invested in Cardiff Oncology in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 12 increasing their positions, 26 reducing their positions, and 8 closing their positions.
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
42% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $911K
14% more funds holding
Funds holding: 58 → 66 (+8)
9% less capital invested
Capital invested by funds: $46.4M → $42.3M (-$4.13M)
54% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 26
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
Top Sellers
CRDF Hedge Fund Activity: Q2 2016 in Review
66 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2016, worth a combined $42.3M — down 8.9% from $46.4M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CRDF positions and 8 closed out — a net gain of 8 holders — while 12 added to existing stakes and 26 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.57M. The largest seller was Morgens Waterfall Vintiadis & Co, cutting an estimated $2.22M.
- 66 institutional investors held Cardiff Oncology (CRDF) as of Q2 2016, up from 58 in Q1 2016.
- Funds reported $42.3M of Cardiff Oncology stock for Q2 2016, down 8.9% quarter-over-quarter.
- 16 funds opened new Cardiff Oncology positions in Q2 2016 and 8 closed out, a net change of +8 holders.
- The largest Cardiff Oncology buyer in Q2 2016 was Morgan Stanley, an estimated $1.57M added.
- The largest Cardiff Oncology seller in Q2 2016 was Morgens Waterfall Vintiadis & Co, an estimated $2.22M sold.
Based on aggregated 13F filings for Q2 2016.